International Journal of Medical and All Body Health Research  |  e-ISSN: 2582-8940  |  Double-Blind Peer Review  |  Open Access  |  CC BY-NC-SA 4.0

Current Issues
     2026:7/4

International Journal of Medical and All Body Health Research

e-ISSN: 2582-8940 | Open Access

Review: Tocilizumab-A protential drug for Covid-19

Anjali Soni, Aanveekshikee Rathore, Dr. Arun K Gupta

Chameli Devi Institute of Pharmacy, Indore, Madhya Pradesh, India

Article Information

Volume / Issue2 / 2 (April-June 2021)
Pages06-07
AccessOpen Access

Publication Timeline

  • Received26 March 2021
  • Accepted13 April 2021

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF) JATS XML

Abstract

Tocilizumab, an interleukin-6 inhibitor, may enhance clinical outcomes by reducing the inflammatory symptoms of severe coronavirus disease 2019 (COVID-19). The reported patients with laboratory-confirmed severe COVID-19 who received tocilizumab and followed up for 14 days were studied retrospectively. However, it is not possible to ascertain which adverse events were directly related to tocilizumab therapy. In patients with severe COVID-19, tocilizumab was associated with dramatic decline in inflammatory markers, radiological improvement and reduced ventilator support requirements. In this work our aim is to conclude that at what stage tocilizumab is used and what outcomes are observed.

Keywords

ContraceptionPost placentalIUCD

References

  1. Samaee H, Mohsenzadegan M, Ala S, Maroufi SS, Moradimajd P. Tocilizumab for treatment patients with COVID-19: recommended medication for novel disease. International immunopharmacology, 2020, 107018. [Google Scholar][Crossref]
  2. Alattar R, Ibrahim TB, Shaar SH, Abdalla S, Shukri K, Daghfal JN, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. Journal of medical virology. 2020; 92(10):2042-2049. [Google Scholar][Crossref]
  3. Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine. 2021; 384(16):1503-1516. [Google Scholar][Crossref]
  4. Klopfenstein T, Zayet S, Lohse A, Selles P, Zahra H, Toko L, et al. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. International Journal of Infectious Diseases. 2020; 99:491-495. [Google Scholar][Crossref]
  5. Kewan T, Covut F, Al–Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study. E Clinical Medicine. 2020; 24:100418. [Google Scholar][Crossref]
  6. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clinical Infectious Diseases. 2021; 73(2):e445-e454. [Google Scholar][Crossref]
  7. Dewi IM, Janssen NA, Rosati D, Bruno M, Netea MG, Brüggemann RJ, et al. Invasive pulmonary aspergillosis associated with viral pneumonitis. Current Opinion in Microbiology. 2021; 62:21-27. [Google Scholar][Crossref]
  8. Kotak S, Khatri M, Malik M, Malik M, Hassan W, Amjad A, et al. Use of tocilizumab in COVID-19: a systematic review and meta-analysis of current evidence. Cureus, 2020, 12(10). [Google Scholar][Crossref]
  9. Huang E, Isonaka S, Yang H, Salce E, Rosales E, Jordan SC. Tocilizumab treatment in critically ill patients with Covid-19: A retrospective observational study. International Journal of Infectious Diseases. 2021; 105:245-251. [Google Scholar][Crossref]
  10. Tsai A, Diawara O, Nahass RG, Brunetti L. Impact of tocilizumab administration on mortality in severe Covid-19. Scientific reports. 2020; 10(1):1-7. [Google Scholar][Crossref]
  11. Vu CA, DeRonde KJ, Vega AD, Maxam M, Holt G, Natori Y, Zamora JG, et al. Effects of Tocilizumab in COVID-19 patients: a cohort study. BMC infectious diseases. 2020; 20(1):1-10. [Google Scholar][Crossref]
  12. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID‐19: a single center experience. Journal of medical virology. 2020; 92(7):814-818. [Google Scholar][Crossref]
  13. Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19. Journal of translational medicine. 2020; 18(1):1-5. [Google Scholar][Crossref]
  14. Kaye AG, Siegel R. The efficacy of IL-6 inhibitor Tocilizumab in reducing severe Covid-19 mortality: A systematic review. Peer J. 2020; 8:p.e10322 [Google Scholar][Crossref]

How to Cite

Soni, A., Rathore, A., & Gupta, A. K. (2021). Review: Tocilizumab-A protential drug for Covid-19. International Journal of Medical and All Body Health Research, 2(2), 06-07.

Soni, Anjali, et al. "Review: Tocilizumab-A protential drug for Covid-19." International Journal of Medical and All Body Health Research, vol. 2, no. 2, 2021, pp. 06-07.

Soni, A., Rathore, A. and Gupta, A. K. (2021) 'Review: Tocilizumab-A protential drug for Covid-19', International Journal of Medical and All Body Health Research, 2(2), pp. 06-07.

Soni A, Rathore A, Gupta AK. Review: Tocilizumab-A protential drug for Covid-19. International Journal of Medical and All Body Health Research. 2021;2(2):06-07.

Similar Articles

Share

Find this Article on

Google Scholar Semantic Scholar OpenAlex ResearchGate BASE

A newly published article may take a few days to appear on these services.